SG/CALL/BRISTOL-MYERS SQUIBB/80/0.1/20.09.24

SG/CALL/BRISTOL-MYERS SQUIBB/80/0.1/20.09.24 Stock

DE000SQ8Z6P0

Delayed Deutsche Boerse AG 02:21:49 2024-06-24 pm EDT
0.001 ^EUR	0.00%

Current year

-90.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/80/0.1/20.09.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	06:47am	AQ
Bristol Myers: accelerated approval in colorectal cancer	01:28am	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	Jun. 21	BU
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	Jun. 21	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-24	0.001	0.00%
24-06-21	0.001	0.00%
24-06-20	0.001	0.00%
24-06-19	0.001	0.00%
24-06-18	0.001	0.00%

Delayed Quote Deutsche Boerse AG

Last update June 24, 2024 at 02:21 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SQ8Z6P
ISIN	DE000SQ8Z6P0
Date issued	2023-02-13
Strike	80 $
Maturity	2024-09-20 (88 Days)
Parity	10 : 1
Emission price	0.58 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.66 €
Lowest since issue	0.001 €
Spread	0.019 €
Spread %	95.00%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.93 USD

Average target price

53.19 USD

Spread / Average Target

+26.87%

Consensus